Roche expands the Global Access Program beyond HIV to also include diagnostic tests for Tuberculosis, Hepatitis, and Human Papillomavirus
- Access to innovative diagnostic solutions will contribute to the World Health Organization’s infectious disease elimination goals
- Improving access to reliable diagnostics for disease management in countries with the highest burden
- Early detection of infectious diseases with diagnostics helps clinicians save lives
Basel, 22 July 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Global Access Program is expanding beyond HIV, to include Mycobacterium tuberculosis (MTB), Hepatitis B and C (HBV and HCV), and Human Papillomavirus (HPV) for low and middle income country programs where the disease burden is the highest. The expansion of the Global Access Program highlights Roche’s commitment to improve access to cost-effective resources, implement scale-up programs, and contribute to the elimination of diseases in the regions with the greatest need.
“With effective treatment options for these infectious agents and improved patients access to diagnostics, early detection can help save lives and ease suffering,” said Michael Heuer, CEO Roche Diagnostics. “As the leader in infectious disease diagnosis testing, Roche is dedicated to support goals on eradicating diseases globally.”
“Access to cutting-edge, best in class diagnostic test results means more patients being appropriately diagnosed and well treated, resulting in lives saved,” stated David Ripin, Chief Science Officer of the Clinton Health Access Initiative (CHAI). "We welcome Roche’s decision to expand access to tests for hepatitis, tuberculosis, and HPV (the leading cause of cervical cancer) to their Global Access Program, providing health systems with transparent and consistent pricing to these important tests in addition to the HIV viral load and early infant diagnostics already established in the program. CHAI values Roche’s continued partnership in the effort to make diagnostics seamlessly available in well optimized diagnostic lab systems throughout the world."
“Accessible pricing can be the difference between a patient getting a quality diagnosis or not,” said Catharina Boehme, CEO of the Foundation for Innovative New Diagnostics (FIND) – a global non-profit devoted to the development and delivery of diagnostics for diseases that include TB and HCV. “FIND is proud to have worked with Roche to expand the Global Access Program for these deadly diseases, leveraging our support for its TB assay.”
Access to screening, early detection and prevention of transmission reduces the spread of disease. Tuberculosis is a major health crisis and is the leading cause of infectious disease deaths worldwide. Access to hepatitis diagnostic tests for HBV and HCV will improve the outlook of eliminating these chronic infections. And screening with HPV DNA testing can more accurately identify women at risk for cervical cancer than other screening methods.1 With vaccination and proper screening, cervical cancer is a preventable disease.2 Importantly, infection with HPV has been found to increase the risk of HIV transmission for both men and women.3 Similarly, women living with HIV are four to 10 times more likely to develop cervical cancer.4 Screening for co-infection (HIV+ HPV) can significantly improve disease management decisions and enable appropriate patient care.
In total, the Global Access Program now includes molecular diagnostics for HIV-1 viral load, HIV-1 and HIV-2 early infant diagnosis, the cobas® Plasma Separation Card - an innovative plasma collection device, MTB and MTB - RIF/INH, Hepatitis B and C, and Human Papillomavirus. All these assays run on the cobas® 4800/6800/8800 platforms for various testing volume needs enabled by the cobas® Plasma Separation Card that transports samples from remote areas/sites to the central lab for further processing.
About World Health Organization disease elimination goals
Optimizing the use of diagnostics will be critical to achieving targets for elimination. The UNAIDS HIV 90:90:90 goal by 2020 states that by 2020, 90% of all people living with HIV will know their HIV status, 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy, and 90% of all people receiving antiretroviral therapy will have durable viral suppression.
For hepatitis, the World Health Organization defined goals aiming at a 90% reduction in new chronic infections and a 65% reduction in mortality in 2030 as compared with the 2015 baseline.5
Cervical cancer is preventable with vaccination, screening, and treatment when necessary. The draft 2030 goals for cervical cancer elimination include 90% vaccination rate for HPV in girls by 15 years of age, 70% of women screened with a high-precision test at 35 and 45 years of age along with appropriate follow-up, and 90% of women identified with cervical disease receive treatment and care.6
The WHO have established goals to end Mycobacterium tuberculosis by 2035 which includes a 95% reduction in death, 90% reduction in incidence, and 0% catastrophic costs.7
About Roche’s Global Access Program
In 2014, Roche announced, the Global Access Program for increased access to HIV diagnostics. Roche partnered with national governments, local healthcare facilities, communities and international agencies, including UNAIDS, CHAI, Unitaid, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), Global Fund, and Center for Disease Control and Prevention (CDC), to establish programs that would go beyond providing diagnostic tests. Since its inception, the program has expanded substantially in menu and geographic footprint to provide increased access to diagnostics at affordable pricing for qualifying organizations in eligible countries with the highest disease burden. Most recently the Global Access Program included the innovative cobas® Plasma Separation Card to provide the only CE-marked plasma sample collection devise which meets the World Health Organization sensitivity standard of < 1000 cp/mL.
According to the World Health Organization (WHO), there are over 36 million people living with HIV around the world.8 Just 21.7 million people are receiving antiretroviral therapy and of those, only 47% are virally suppressed.9
Tuberculosis is a major global health problem, and is the leading cause of infectious disease deaths worldwide.10 The World Health Organization (WHO) estimates that about 1.7 billion people are infected with MTB, with an estimated 10.0 million new TB infections, and over 1.6 million deaths in 2017.
Viral hepatitis remains a major public health burden killing more than 1.34 million people annually and mortality is on the rise.11 71 million are estimated to be infected with chronic hepatitis C12 ; whereas, 257 million are estimated to be infected with hepatitis B.13 The majority of disease burden is in low- and middle-income countries.
According to the WHO, there are approximately 570,000 new cases of cervical cancer and 311,000 deaths globally each year, with close to 90% of these occurring in low- and middle-income countries.14,15 Human Papillomavirus (HPV) is the cause of nearly all cases so screening for HPV DNA can identify women at risk; with proper vaccination, screening and treatment, nearly 100% of cervical cancers can be eliminated.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
*Not all products and uses are available in all countries. Please refer to the package insert for applicable intended uses for each individual product.
 Wentzensen N, et al. HPV-based cervical cancer screening- facts, fiction, and misperceptions. Prev Med. 2017;98:33-5
 https://www.who.int/reproductivehealth/call-to-action-elimination-cervical-cancer/en/ Retreived 08Jul2019
 http://www.unaids.org/en/cervical_cancer . Accessed 1Nov2018
 WHO draft global strategy towards the elimination of cervical cancer as a public health problem https://www.who.int/docs/default-source/documents/cervical-cancer-elimination-draft-strategy.pdf. Accessed 11Jun2019.
 WHO. GLOBAL HEALTH SECTOR STRATEGY ON VIRAL HEPATITIS 2016–2021. 2016
 Source: WHO draft global strategy towards the elimination of cervical cancer as a public health problem
https://www.who.int/docs/default-source/documents/cervical-cancer-elimination-draft-strategy.pdf Accessed 11Jun2019
 http://www.who.int/tb/post2015_strategy/en/ . Accessed 1Nov2018
 WHO HIV Key Facts. http://www.who.int/en/news-room/fact-sheets/detail/hiv-aids . Accessed 15Oct2018.
  UNAIDS Global HIV & AIDS statistics — 2018 fact sheet. WHO HIV Key Facts.
http://www.who.int/en/news-room/fact-sheets/detail/hiv-aids. Accessed 18Oct2018.
 World Health Organization. Global tuberculosis report 2018. Geneva, Switzerland; WHO, 2018.
 Global Hepatitis Report 2017 - World Health Organization. April 2017
 Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176.
 Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018.
 Bray F, Ferlay J, Soerjomataram I, Dikshit R, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians; 68(6): 394-424
 http://www.who.int/cancer/prevention/diagnosis-screening/cervical-cancer/en/. Accessed 5Nov2018
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: firstname.lastname@example.org
- Nicolas Dunant (Head)
- Patrick Barth
- Ulrike Engels-Lange
- Karsten Kleine
- Barbara von Schnurbein
- Anja von Treskow
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Stephanie Werner appointed Chief Human Resources Officer and a member of the Nokia Group Leadership team as Hans-Jürgen Bill retires 12.12.2019 08:30:00 CET | Press release
Nokia Corporation Stock Exchange Release December 12, 2019 at 9.30 (CET +1) Stephanie Werner appointed Chief Human Resources Officer and a member of the Nokia Group Leadership team as Hans-Jürgen Bill retires Espoo, Finland – Nokia today announced the appointment of Stephanie Werner, as Chief Human Resources Officer, effective January 1, 2020. Hans-Jürgen Bill, Nokia’s current Chief Human Resources Officer, will retire in May 2020. Stephanie Werner has been with Nokia since 1998 and has held various HR leadership positions in countries including China, Switzerland, Philippines, USA and Romania. She will be based in Finland. “I am pleased to be able to welcome Stephanie to take the lead on our people strategy during a critical time for Nokia,” said Rajeev Suri, President and Chief Executive Officer of Nokia. “She will play a key role in enabling our ongoing transformation and building a high-performance culture. I want to thank Hans-Jürgen for his many contributions to Nokia and wish hi
Aino Health AB (publ): Aino Health tecknar avtal med Centric Sverige gällande SaaS-lösningen HealthManager12.12.2019 08:25:00 CET | Pressemelding
Aino Health hat tecknat ett avtal, gällande SaaS-lösningen HealthManager, med Centric – ett It-företag som erbjuder konsulttjänster och IT outsourcing. Avtalet löper initialt över två år. I den första fasen kommer HealthManager att implementeras för ca 350 personer i Sverige, av de totalt 800 personer som är anställda i Norden. Centric har totalt 4500 anställda i Europa fördelat på 7 olika länder. Centric har letat efter en lösning som kan hjälpa dem att arbeta mer effektivt och strukturerat när det gäller de anställdas välmående och hälsa och som samtidigt kan stötta cheferna arbetssätt gällande detta. Målen med implementationen är högre närvaro och välmående hos de anställda. Projektets första fas är planerad att vara implementerad i december i år. HealthManager är en SaaS plattform som stöttar chefer med intern hälsorelaterade processer och frånvarohantering. kommunikation och engagemang. Tjänsten erbjuder verktyg för rapportering och analys för att följa nyckeltal kopplade till Cor
Aino Health AB (publ): Aino Health signs agreement with Centric Sweden regarding the SaaS solution HealthManager12.12.2019 08:25:00 CET | Press release
Aino Health has signed an agreement, regarding the SaaS solution HealthManager, with Centric - an IT company offering consultants as well as IT outsourcing. The initial agreement is a two-year contract. In the first phase, HealthManager will be implemented for around 350 persons in Sweden out of the in total about 800 Centric employees in the Nordics. In Europe, Centric has more than 4500 employees in 7 countries. Centric has been looking for a solution that can help them to work in a more structural and efficient way regarding employee wellbeing and health, and at the same time support the managers’ way of working with this. The goals are to increase presence at work and the wellbeing of the personnel. The first phase of the project is projected to be live in December this year. HealthManager is a SaaS solution that supports managers with internal health-related processes and absence management. It also offers reporting and analytic tools to follow key metrics related to corporate hea
Nokia wins Deutsche Bahn tender to deliver and test the world’s first 5G-based network for automated rail operation12.12.2019 08:15:00 CET | Press release
Press Release The solution is one of the world’s first standalone 5G networks used for automated rail operation. The project constitutes an essential milestone in the development of the 5G-based Future Railway Mobile Communication System (FRMCS) standard — the successor to the current GSM-R standard 12 December 2019 Espoo, Finland – Nokia has won a tender to test and deliver the world’s first standalone (SA) 5G system for automated rail operation in Hamburg, Germany. The project is part of Deutsche Bahn’s highly automated S-Bahn operation project. The proof-of-concept will test whether 5G technology is mature enough to be used as the connectivity layer for future, digitalized rail operations. The project constitutes an early and important step in the development of the Future Railway Mobile Communications System (FRMCS) standard, based on 5G, and sets the stage for the digital transformation of railway operations. Nokia is a leader in this market with extensive experience in providing
PRF: Change in the management board of Osaühing Vettel12.12.2019 08:09:00 CET | Press release
Dagni Viskus was elected as a management board member of Osaühing Vettel (subsidiary of AS PRFoods) being responsible for production management in Saaremaa. Dagni Viskus was previously working in Osaühing Vettel as a quality manager. Dagni Viskus has no shares of AS PRFoods. Besides Dagni Viskus, Indrek Kasela and Jarkko Tapani Alho are members of the management board of Osaühing Vettel. Indrek Kasela AS PRFoods Member of the Management Board Phone: +372 452 1470 email@example.com www.prfoods.ee
SpareBank 1 SMN: Mandatory notification of trade – SpareBank 1 SMN’s savings programme allocates equity certificates12.12.2019 08:08:00 CET | Press release
SpareBank 1 SMN – Mandatory notification of trade – SpareBank 1 SMN’s savings programme allocates equity certificates The equity certificates purchased by SpareBank 1 SMN on 6 and 9 December 2019 for use in the group’s savings programme for employees, have been distributed to the employees at a price of NOK 97.78 per equity certificate in accordance with their savings amount. Following this, the savings programme has 704,242 equity certificates. After allocation the bank owns 625 equity certificates. As participants in the savings programme, the primary insiders below have been allocated equity certificates as follows: Name: Allocated no. equity certificates: New total holding of equity certificates*: Cathrine Aunvik 63 1,461 Rolf Jarle Brøske 63 7,134 Tomm Bøyesen 63 5,823 Kjell Fordal 63 245,883 Vegard Helland 63 34,773 Kjersti Hønstad 63 4,485 Inge Lindseth 63 4,034 Nelly Maske 63 20,854 Ola Neråsen 63 42,335 Margrethe L. Resellmo 17 398 Berit Rustad 63 3,546 Camilla Stang 17 398 Ch